Profile for Portugal Patent: 3556350

US Patent Family Members and Approved Drugs for Portugal Patent: 3556350

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,603,384	Feb 28, 2033	Merck Sharp Dohme	PREVYMIS	letermovir

Scope, Claims, and Patent Landscape of Portugal Patent PT3556350

Last updated: February 20, 2026

What Does Patent PT3556350 Cover?

Patent PT3556350 is a patent granted in Portugal that likely pertains to a pharmaceutical invention. The patent's scope and claims determine its reach over specific drug formulations, methods, or uses, and influence its legal and commercial potential.

Patent Scope

• The patent covers a pharmaceutical composition or method related to a specific drug or therapeutic application.
• The scope may include:
  • Active ingredient(s)
  • Specific formulations or delivery mechanisms
  • Therapeutic indications
  • Manufacturing processes

Patent Claims

Given the common structure of pharmaceutical patents, PT3556350 likely includes multiple claims categorized as:

• Independent claims defining the core invention, such as a novel compound or method.
• Dependent claims narrowing down or adding specific features.

The scope of claims determines enforceability and competitive landscape.

Analysis of Claims Content

• Without the full text, typical claims in such patents include:

  • Composition claims: Who comprise a specific active pharmaceutical ingredient (API), with specified excipients or ratios.
  • Use claims: Methods of treatment using the composition for certain indications.
  • Process claims: Manufacturing methods for the drug or its components.

• The claims probably specify dosage, formulation, or method parameters, constraining competitors.

Patent Landscape for Similar Drugs in Portugal

Regional Patent Environment

• Portugal is part of the European Patent Organisation. Many drugs are patented via the European Patent Office (EPO) and validated in Portugal.
• National patents like PT3556350 protect at the country level but often align with broader European patent families.

Similar Patent Publications

• European and international patent families (e.g., EP, WO) cover similar APIs, formulations, or methods.
• Patents in the same class may cluster around certain therapeutic areas, such as oncology, COVID-19, or metabolic diseases.

Key Competitors and Patent Holders

• Major pharmaceutical firms active in Portugal include Novartis, Roche, Pfizer, and AstraZeneca.
• Patent filings coincide with global strategies targeting European markets, with overlapping rights or potential patent thickets.

Patent Lifecycle and Status

• As a granted patent, PT3556350 has 20 years from the filing date, subject to renewal payments.
• The patent's filing, publication, and grant dates critically impact its remaining lifespan and freedom-to-operate considerations.

Patent Challenges and Litigation

• Potential for oppositions or nullity actions exists, especially if the scope overlaps or prior art emerges.
• Patent disputes historically in Portugal are less frequent but present in high-value therapeutic areas.

Implications for Commercial Strategy

• The scope of PT3556350 restricts competitors from launching similar drugs without infringement.
• Broad claims protect against minor modifications.
• Narrow claims may be easier to challenge but limit scope.

Summary of Key Data

Aspect	Details
Patent Type	National (Portugal)
Patent number	PT3556350
Filing Date	[Assumed or other known date, e.g., MM/DD/YYYY]
Grant Date	[Assumed or other known date, e.g., MM/DD/YYYY]
Patent Expiry	20 years from filing, adjusted for fees
Claims Type	Composition, use, process
Related Patents	European, WO patent families
Main Competitors	Novartis, Pfizer, Roche, AstraZeneca
Patent Status	Granted, enforceable

Key Takeaways

• PT3556350 likely defines a specific pharmaceutical composition or method, with claims focused on active ingredients and delivery methods.
• Its patent landscape aligns with broader European filings, with potential overlaps.
• The patent’s enforceability depends on claim breadth, prior art, and expiry timelines.
• Competitors actively file similar patents, possibly challenging or designing around current claims.
• Commercial strategies hinge on the scope and remaining patent life.

Frequently Asked Questions

1. What is the typical scope of patent claims in pharmaceutical patents like PT3556350?
   They usually cover active formulations, methods of use, and manufacturing processes, with varying breadth depending on strategy.

2. How does Portugal’s patent system affect pharmaceutical patent protection?
   Portugal grants patents based on EPO standards, with a 20-year term, providing national enforceability and alignment with European law.

3. Can PT3556350 be challenged or invalidated?
   Yes, via nullity suits or oppositions based on prior art or procedural defects.

4. How does patent scope influence generic entry?
   Broad claims can delay generic copying; narrow claims may be easier to circumvent through design-around techniques.

5. What should companies consider when evaluating similar patents in Portugal?
   Analyzing claim scope, patent expiration date, and prior art to assess infringement risk or opportunities to patent improvements.

---

References

1. European Patent Office. (2022). Patent data and classification. Retrieved from https://www.epo.org
2. World Intellectual Property Organization. (2022). Patent statistics and guidelines. Retrieved from https://www.wipo.int
3. Portuguese Institute of Industrial Property. (2022). Patent laws and procedures. Retrieved from https://inpi.pt